Table 3.
Associations with discontinuation in placebo group (n = 85).
| Successful discontinuation (continuing placebo) (n = 23) |
Unsuccessful discontinuation (discontinuing placebo) (n = 62) |
p value∗ | |
|---|---|---|---|
| Age median (IQR), year | 58 (48–62) | 60 (51–69) | 0.81 |
| Male (%) | 23% | 58% | 0.003 |
| Helicobacter pylori-positive, % (95% CI) | 29 (12–51) | 17 (8–29) | 0.24 |
| No nicotine use, % (95% CI) | 68 (46–85) | 50 (37–63) | 0.12 |
| Alcohol use, <21 units/weeks, % (95% CI) | 92 (74–99) | 92 (82–97) | 0.96 |
| Symptom duration, median (10%; 90%) percentile, year | 4 (0–13) | 4 (1–14) | 0.21 |
| Previous endoscopy, % (95% CI) | 40 (21–61) | 47 (24–60) | 0.58 |
| Previous NSAID/ASA use, % (95% CI) | 60 (39–79) | 62 (48–74) | 0.89 |
| GSRS total, mean (95% CI) | 2.5 (2.2–2.8) | 2.9 (2.5–3.2) | 0.07 |
| GSRS reflux score, mean (95% CI) | 3.0 (2.5–3.5) | 3.3 (2.9–3.8) | 0.29 |
| SF-36 physical health summary score, mean score (95% CI) | 41 (36–46) | 43 (40–46) | 0.54 |
| SF-36 mental health summary score, mean score (95% CI) | 48 (42–54) | 51 (49–54) | 0.20 |
∗ F-test for linear regression.